medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2018, Number 5

<< Back Next >>

Rev Mex Urol 2018; 78 (5)

Testicular cancer: Incidence, epidemiology and etiology. Five years of experience at the Hospital General de México Dr. Eduardo Liceaga

Gurrola-Ortega Á, Sánchez-Núñez JE, Rivera-Astorga H, Magaña-González JE, Sarabia-Estrada RC, Garduño-Arteaga LM, Manzanilla-García HA, Jaspersen-Gastelum J

Language: Spanish
References: 20
Page: 347-353
PDF size: 338.80 Kb.


ABSTRACT

Background: Testicular cancer accounts for 5% of the tumors in reproductive-age men and there has recently been an increase in its incidence. Diagnosis is made through clinical evaluation, tumor markers, and testicular ultrasound. Histologic strain determines treatment response and outcome.
Objective: To report the epidemiologic, histopathologic, and etiologic characteristics of testicular cancer at a tertiary care hospital within the time frame of 2012-2017.
Materials and Methods: A retrospective, observational, and descriptive study was conducted on patients with the diagnosis of testicular cancer of any histologic strain seen at the urology service of the Hospital General de México within the time frame of 2012 to 2017. The qualitative variables were expressed as simple, relative frequencies in percentages. Frequency variability was obtained through the 95% CI. Age were expressed in median and maximum and minimum values. The chi-square test and the Kruskal-Wallis test were employed to contrast the differences between tumor types, according to the variables analyzed.
Results: A total of 142 patients were studied, 44.4% of whom presented with mixed germ cell tumors and 43.7% with classic seminomas. Fifty percent of the patients presented with the disease at 20 to 30 years of age (mean 35.5). With respect to laterality, 56.3% of the tumors were on the left side and 43.7% on the right. In relation to lymph node dissemination (N) of the seminomatous tumors, 80.6% of the cases (n = 50) were stage N0 and 95.2% (n = 59) did not present with pulmonary metastasis, or any other, at the time of diagnosis. Of the nonseminomatous tumors (mixed germ cell tumors), 57.2% (n = 36) were stage N0 and 87.3% (n = 55) were M0. There was a slight increase in testicular cancer in the last two years.
Conclusions: Despite our results, we believe a different study methodology is required to determine the cause of testicular cancer in our population.


REFERENCES

  1. Coursey-Moreno C, et al. Testicular tumors: what radiologists need to know–differential diagnosis, staging, and management. Radiographics 2015;35(2):400-15. https:// doi.org/10.1148/rg.352140097

  2. Jiménez-Rios M. Panorama epidemiológico del cáncer genitourinario en la Zona Centro de México. Rev Mex Urol 2011;71(S3): 3-6.

  3. Albers P, et al. Guidelines on Testicular Cancer: 2015 Update. European Urology 2015;68(6): 1054-68. https://doi. org/10.1016/j.eururo.2015.07.044

  4. Walsh TJ. Incidence of testicular germ cell cancers in U.S. children: SEER program experience 1973 to 2000. Urology 2006; 68(2):402-5. https://doi.org/10.1016/j. urology.2006.02.045

  5. Gómez A, et al. Incidencia de cáncer en una Unidad de atención Oncológica del Instituto Mexicano del Seguro Social (IMSS) en Toluca, Estado de México. Rev Gac Med Mex 2014; 150(2):297-303.

  6. Nigam M, et al. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World Journal of Urology 2015;33(5):623-31. https://doi. org/10.1007/s00345-014-1361-y

  7. Lindsey AT, et al. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. Cancer J Clin 2016;66(1):7- 30. https://doi.org/10.3322/caac.21335

  8. Zachary L. Testicular Cancer Epidemiology, Diagnosis, and Management. Med Clin N Am 2018; 251-64. doi: 10.1016/j. mcna.2017.10.003.

  9. Hemminki K, et al. Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br J Cancer 2004; 90: 1765-70. https://doi.org/10.1038/ sj.bjc.6601714

  10. Leveridge MJ, et al. Temporal trends in management and outcomes of testicular cancer: A Population-Based Study. Cancer J 2018;124(13):2724-32. doi: 10.1002/cncr.31390.

  11. Shanmugalingam T, et al. Global incidence and outcome of testicular cancer. Clin Epidemiol 2013; 5: 417-27. doi: 10.2147/CLEP.S34430

  12. Dogra VS, et al. Sonography of the scrotum. Radiology 2003;227(1): 18-36. doi 10.1148/radiol.2271001744

  13. See W, et al. Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. J Urol 1993;150(3):874-78. https://doi.org/10.1016/ S0022-5347(17)35637-9

  14. Chia VM, et al. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev 2010; 19:1151-59. doi: 10.1158/1055-9965. EPI-10-0031

  15. Rajpert-De Meyts E. et al. Testicular germ cell tumours. Lancet 2016;387(10029):1762-74. doi: 10.1016/S0140- 6736(15)00991-5.

  16. Beck SDW, et al. Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer. Urol Oncol 2005;23(6):423-30. doi:10.1016/j. urolonc.2005.06.007

  17. Beck SD, et al. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in postchemotherapy nonseminomatous testis cancer. J Urol 2002;168(4 Pt 1):1402-4. doi: 10.1097/01. ju.0000027902.28824.71

  18. Travis LB, et al. Second cancers among 40,576 testicular cancer patients: focus on long term survivors. J Natl Cancer Inst 2005;97(18):1354-65. https://doi.org/10.1093/ jnci/dji278

  19. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15(2):594-603. http://hdl.handle. net/10541/94716

  20. Mohamed A. Adult testicular cancer: Two decades of Saudi national data. Urol Ann 2017;9(4):305-9. doi: 10.4103/ UA.UA 11 17




2020     |     www.medigraphic.com